yahoo_financeOriginal article
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Phase 3positiveEnhertuPositive
AI Analysis
Summary
Enhertu demonstrated a median progression-free survival of 14.3 months as first-line therapy in patients with HER2 mutant advanced non-small cell lung cancer in the Phase 3 DESTINY-Lung04 trial.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Median progression-free survival of 14.3 months as first-line therapy
Importance:7/10
Sentiment:
0.75
EnhertuDESTINY-Lung04HER2 mutantNSCLCprogression-free survivalfirst-line therapy
Related Companies
Read the original article
Published by yahoo_finance on September 14, 2026 1:45 AM